Register
Login:
Share:
Email Facebook Twitter




Valirx Regulatory News (VAL)



Regulatory News for Valirx (VAL)


Share Price: 10.00Bid: 9.50Ask: 10.50Change: 0.00 (0.00%)No Movement on Valirx
Spread: 1.00Spread as %: 10.53%Open: 10.50High: 11.50Low: 9.75Yesterday’s Close: 10.00





Update

Wed, 31st Jul 2013 07:00

RNS Number : 5154K
ValiRx PLC
31 July 2013

?

31 July 2013

ValiRx Plc

("ValiRx" or the "Company")

Update

ValiRx Plc (AIM: VAL), a life science company with a focus on cancer therapeutics for personalised medicine, provides an update on recent activity and progress:

VAL201

The Company confirms that VAL201, its leading anti-cancer therapeutic, continues to progress through its clinical development on all fronts. This is a "First-in-(Hu)Man"study involving cancer patients, as opposed to healthy volunteers, and is a phase 1 trial.

It should be noted that activity on VAL201, that includes the required scientific, ethical, technical and legal work, with all supporting evidential material and documentation needed to finalise the reporting of the study (of which the trial forms part), is proceeding according to plan. Currently, all tasks that can or could impact the critical path of the VAL201 development programme are understood and controlled and none is giving undue concern that the outcome or the timing of the study will be adversely affected.

As previously reported on 13 June 2013, ValiRx anticipates that results of the phase 1 trial will be available before the end of 2013.

GeneICE

VAL101, the lead candidate deriving from the GeneICE platform, is progressing to the final preclinical "proof of concept" stage with pharmacokinetics (PK) and pharmacodynamics (PD) and preliminary toxicology studies underway. The work is being undertaken at the University of Heidelberg, Germany, which is the centre at which the lead investigator is now based following a move from Imperial College in London in the spring of this year.

Eurostars Grant

The Eurostars grant that was previously awarded to a consortium led by ValiRx has now been successfully completed and this completion has been accepted by both the Technology Strategy Board (TSB) and the Eurostars Team. Furthermore, the Company has received notification from the TSB and Eurostars Team that it is eligible for a new grant which includes work on VAL101 and Biomarkers.

- ENDS -

For more information, please contact:

ValiRx plc

Tel: +44 (0) 20 3008 4416

Dr Satu Vainikka

www.ValiRx.com



Cairn Financial Advisers LLP (Nominated Adviser)

Tel:+44 (0) 20 7148 7900

Liam Murray / Avi Robinson




Hybridan LLP (Broker)

Tel: +44 (0) 20 7947 4350 / 4361

Claire Louise Noyce / William Lynne




Peckwater PR

Tel: +44 (0)7879 458 364

Tarquin Edwards

tarquin.edwards@peckwaterpr.co.uk



Notes for Editors

ValiRx Plc

ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.

The Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.

The Company operates through the following divisional companies:

ValiFinn is the biomarkers and diagnostic development division

ValiPharma is the therapeutics division with two embedded technologies primarily directed at the treatment of cancers.





This information is provided by RNS
The company news service from the London Stock Exchange
END
RESBUGDRIXXBGXG


Related Shares:
Valirx (VAL)




DateSourceHeadlineCategory
29-Apr-16 07:00RNSNotification of US Patent Grant for VAL401Company Announcement - General
26-Apr-16 12:07RNSIssue of EquityCompany Announcement - General
22-Apr-16 10:01RNS-RValiRx to exhibit at the UK Investor ShowCompany Announcement - General
19-Apr-16 15:32RNSIssue of Equity - conversion of loan noteCompany Announcement - General
18-Apr-16 17:00RNSIssue of Equity - conversion of loan noteCompany Announcement - General
01-Apr-16 15:10RNSConversion of Loan Note, issue of warrant & equityCompany Announcement - General
31-Mar-16 07:00RNS-RValiRx to exhibit and present at the AACRCompany Announcement - General
21-Mar-16 07:00RNSConvertible Loan Facility of up to 4.0 millionCompany Announcement - General
17-Mar-16 07:00RNS-RValiRx engages US investor relations firmCompany Announcement - General
17-Feb-16 13:00RNSPlacing to raise 0.5 millionCompany Announcement - General
16-Feb-16 07:00RNSVAL201 Clinical Trial UpdateCompany Announcement - General
09-Feb-16 07:00RNSQuarterly Update on Clinical ProgressCompany Announcement - General
11-Dec-15 09:30RNS-RValiRx to present at Shares Investor MeetingCompany Announcement - General
19-Nov-15 10:45RNSClinical Phase Development UpdateCompany Announcement - General
05-Nov-15 07:00RNSValiRx establishes US office in Boston, MACompany Announcement - General
27-Oct-15 07:00RNSCollaboration AgreementCompany Announcement - General
01-Oct-15 07:00RNSNew Japanese Patent GrantCompany Announcement - General
17-Sep-15 12:15RNSHalf Yearly ReportResults and Trading Reports
16-Sep-15 07:00RNSSubscription and Equity SwapCompany Announcement - General
06-Aug-15 07:00RNSCollaboration and Research Studentship AgreementCompany Announcement - General
21-Jul-15 07:00RNSVAL201 Clinical Trial UpdateCompany Announcement - General
16-Jul-15 07:00RNSValiSeek Clinical Development UpdateCompany Announcement - General
29-Jun-15 07:00RNSGrant of optionsDirectors' Dealings
25-Jun-15 07:00RNSUPDATE on VAL201 Clinical TrialCompany Announcement - General
03-Jun-15 07:00RNSChange of AdviserExecutive Changes
27-May-15 11:22RNSStmnt re Share Price MovementCompany Announcement - General
15-May-15 14:45RNSResult of AGM and Capital ReorganisationResults and Trading Reports
14-May-15 15:50RNSNotification of US Patent Grant Allowance reVAL401Company Announcement - General
14-May-15 07:00RNSValiSeek Development UpdateCompany Announcement - General
07-May-15 07:00RNSRe ContractCompany Announcement - General


Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.